

Preliminary Attendee List Released for Orphan Drugs & Rare Diseases Conference in London

In the run up to the 8th Orphan Drugs & Rare Diseases Conference, the preliminary attendee list has been released and is available to download on the website.

LONDON, WATERLOO, UNITED KINGDOM, October 8, 2018 /EINPresswire.com/ -- With just over 1 week to go until SMI's [8th annual conference on Orphan Drugs & Rare Diseases](#), taking place 17th – 18th October in London, the preliminary attendee list has just been released and is available to download on the website.

Conference attendees will have the exclusive opportunity of meeting and networking with a host of scientific pioneers and industry leaders.

Organisations that have already confirmed their attendance to this year's event include:

- AKU Society
- AstraZeneca
- BioMarin Europe Ltd
- Chiesi Farmaceutici S.p.A.
- Clintec International Ltd
- DEBRA UK
- HealX Limited
- Incisive Health
- Iuna Pharma Consulting Ltd
- Mallinckrodt
- MEDEExpansion
- Mereo BioPharma
- MHRA Minoryx Therapeutics S.L.
- Muscular Dystrophy UK
- NICE
- Niemann-Pick UK
- NSPM Limited
- Pakistan Public Health Association
- Pharma Innovation Consultancy
- Pulse Inframe
- Rare Disease UK
- Sanofi UK
- Sobi



The poster for the 8th annual conference on Orphan Drugs & Rare Diseases, organized by SMI. It features the SMI logo at the top left, followed by the title 'Orphan Drugs & Rare Diseases' in large blue font. Below the title is a graphic of a molecular structure with the hashtag #smiorphandrugs. To the right, a blue box contains the dates '17 - 18 October 2018' and the location 'London, UK'. At the bottom, a black bar displays the website 'www.orphandrugs.co.uk' in white text. Below the poster, the text 'Orphan Drugs and Rare Diseases 2018' is visible.

- University of Groningen
- Pfizer Pharma and many more...

The full list is available to download on the event website, as well as the conference brochure, agenda and full speaker line-up.

On the 16th October, SMi will also host a [pre-conference interactive workshop](#) on "Working together for HTA in rare diseases - A step too far or the way forward?". The workshop will be led by Josie Godfrey, Director at JG Zebra Consulting, who will provide key industry updates and explore important new case studies, as well as reports on this year's relevant topics.

With the event just over 1 week away and places becoming increasingly limited, potential delegates are urged to book soon to avoid missing out. [3 key reasons to attend](#) the two-day conference on Orphan Drugs & Rare Diseases include:

- Explore first-hand the alliances between regulatory agencies, pharmaceutical companies, non-profit organisations and orphan drugs developers, and how collaboration can benefit the development of rare disease therapies
- Hear the latest advancements in the clinical development of orphan drugs for rare diseases, as well as key updates in the pricing and reimbursement of orphan drugs
- Take advantage of 5+ hours of dedicated networking with an unrivalled gathering of industry-leading pharmaceutical companies and patient organisations

Download the latest brochure and exclusive preliminary attendee list on the event website, where you can also register for the conference and accompanying workshop at: <http://www.orphandrugs.co.uk/einpr>

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Maria Mandic
SMi Group
+44 (0) 207 827 6124
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.